翠微股份(603123.SH):控股股東擬受讓海淀科技所持公司9.97%股份
格隆匯3月25日丨翠微股份(603123.SH)公佈,公司於2021年3月25日接到公司控股股東翠微集團通知,翠微集團擬通過協議轉讓方式收購其一致行動人北京海淀科技發展有限公司(以下簡稱“海淀科技”)持有的公司7962.38萬股有限售條件的流通股股份,該等股份佔公司總股本的9.97%。交易雙方已於2021年3月25日簽署了股份轉讓協議及其補充協議。
公司控股股東北京翠微集團本次權益變動屬於增持,北京海淀科技發展有限公司公司本次權益變動屬於減持,北京市海淀區國有資本經營管理中心持股權益不變。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.